Skip to content Loading

Free & discreet shipping on all plans

Licensed Doctors in all 50 states

Wegovy® (Injection)

Regular price  $1,059.00
Sale price  $1,059.00 Regular price 
Branded GLP-1 · Injection

Brand-name Wegovy® for weight loss

FDA-approved Wegovy® (semaglutide) — a once-weekly GLP-1 pen indicated for weight management, reviewed online by licensed U.S. providers.

FDA-approvedBrand-nameOnce weekly
Licensed U.S. providers
Free discreet shipping
Insurance & Medicare
Ongoing support

Overview

Wegovy® (semaglutide) is a brand-name, FDA-approved once-weekly GLP-1 injection from Novo Nordisk, specifically indicated for chronic weight management in eligible adults and adolescents.

Brand-name GLP-1 weight loss delivered to your door
Brand-name care, delivered to your door

How Wegovy® works

Curbs appetite

Acts on the brain’s appetite centers to reduce hunger and cravings.

Slows digestion

Keeps you fuller for longer so you eat less.

Higher weight-loss dose

Dosed up to 2.4 mg — the level studied for weight management.

At a glance — technical specifications

Active ingredient Semaglutide
Manufacturer Novo Nordisk (brand-name)
Drug class GLP-1 receptor agonist (incretin mimetic)
What it does Indicated for chronic weight management — reduces appetite and supports long-term weight loss
How it works Mimics GLP-1 — acts on appetite centers and slows gastric emptying
Form Prefilled injection pen
Administration Once weekly; self-injected
Dose range 0.25 mg → 2.4 mg (gradual titration)
FDA status FDA-approved (June 2021) for chronic weight management; also approved to reduce cardiovascular risk in adults with cardiovascular disease and overweight or obesity
Prescription Required — issued after licensed provider review
Storage Refrigerate 36–46°F (2–8°C); protect from light

Key benefits

Authentic brand-name, FDA-approved for weight loss
Once-weekly prefilled pen
Clinically demonstrated, significant weight loss
Cardiovascular risk reduction in eligible patients

The science

~15%

Average body-weight reduction with Wegovy® (semaglutide 2.4 mg) over 68 weeks in the STEP trials, alongside diet and exercise — among the strongest results for a single-agent GLP-1.* Individual results vary.

FDA status

FDA-approved — Wegovy® (semaglutide) has been FDA-approved since June 2021 for chronic weight management, with an added cardiovascular risk-reduction indication.

What’s included with Mediclab

  • Review by a licensed U.S. provider (all 50 states)
  • Personalized treatment plan & titration
  • Ongoing follow-up & refills
  • Free shipping — HSA/FSA, insurance & Medicare may apply

Safety & side effects

Common effects include nausea, constipation, diarrhea, and vomiting, usually easing over time. Wegovy® carries a boxed warning regarding the risk of thyroid C-cell tumors; do not use with a personal or family history of medullary thyroid carcinoma or MEN2. Discuss any history of pancreatitis or gallbladder disease with your provider.

*STEP clinical trial program (semaglutide 2.4 mg). Wegovy® is a registered trademark of Novo Nordisk A/S. Mediclab is not affiliated with, sponsored by, or endorsed by the trademark owner. Prescription required; dispensed only after provider review and approval. This information is for educational purposes only and is not medical advice. Individual results vary.

Dose: 0.25 mg
In - stock and ready to ship
Start your 2-minute assessment

Prescription products require an online provider review. You pay $0 unless a licensed provider prescribes.

Free shipping

Easy return

Safe checkout

Complete The Look
Wegovy® (Injection)

Wegovy® (Injection)

Regular price  $1,059.00
Sale price  $1,059.00 Regular price 
0.25 mg
Your cart
Your cart is empty
Have an account? Log in to check out faster.
Continue shopping Continue shopping
Cart total $0.00 USD
Product image Product information Quantity Product total